DOP2011000270A - Derivados de ciclopropilamida dirigidos contra el receptor de histamina h3 - Google Patents
Derivados de ciclopropilamida dirigidos contra el receptor de histamina h3Info
- Publication number
- DOP2011000270A DOP2011000270A DO2011000270A DO2011000270A DOP2011000270A DO P2011000270 A DOP2011000270 A DO P2011000270A DO 2011000270 A DO2011000270 A DO 2011000270A DO 2011000270 A DO2011000270 A DO 2011000270A DO P2011000270 A DOP2011000270 A DO P2011000270A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- cyclopropilamide
- directed against
- derivatives directed
- histamine
- receiver
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
- C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/108—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
Abstract
En la presente se divulga al menos un derivado de ciclopropilamida, al menos una composición farmacéutica que comprende al menos un derivado de ciclopropilamida de los aquí divulgados y al menos un método para utilizar al menos un derivado de ciclopropilamida aquí divulgado para el tratamiento de al menos una afección vinculada al receptor H3 de la histamina.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15406709P | 2009-02-20 | 2009-02-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
DOP2011000270A true DOP2011000270A (es) | 2012-08-31 |
Family
ID=42631518
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2011000270A DOP2011000270A (es) | 2009-02-20 | 2011-08-19 | Derivados de ciclopropilamida dirigidos contra el receptor de histamina h3 |
Country Status (39)
Country | Link |
---|---|
US (3) | US8993577B2 (es) |
EP (1) | EP2398780B1 (es) |
JP (2) | JP5666480B2 (es) |
KR (1) | KR20110126628A (es) |
CN (2) | CN102405213B (es) |
AR (1) | AR075531A1 (es) |
AU (1) | AU2010216454B2 (es) |
BR (1) | BRPI1007817A2 (es) |
CA (1) | CA2752796A1 (es) |
CO (1) | CO6400219A2 (es) |
CR (1) | CR20110447A (es) |
CU (2) | CU20110161A7 (es) |
DK (1) | DK2398780T3 (es) |
DO (1) | DOP2011000270A (es) |
EA (2) | EA020093B1 (es) |
EC (1) | ECSP11011280A (es) |
ES (1) | ES2416464T3 (es) |
HK (2) | HK1164863A1 (es) |
HN (1) | HN2011002261A (es) |
HR (1) | HRP20130579T1 (es) |
IL (1) | IL214277A (es) |
ME (1) | ME01619B (es) |
MX (1) | MX2011008280A (es) |
NI (1) | NI201100160A (es) |
NZ (1) | NZ595248A (es) |
PE (2) | PE20151281A1 (es) |
PL (1) | PL2398780T3 (es) |
PT (1) | PT2398780E (es) |
RS (1) | RS52851B (es) |
SA (1) | SA110310136B1 (es) |
SG (1) | SG173449A1 (es) |
SI (1) | SI2398780T1 (es) |
SM (1) | SMT201300077B (es) |
SV (1) | SV2011004008A (es) |
TW (1) | TW201039825A (es) |
UA (1) | UA108841C2 (es) |
UY (1) | UY32460A (es) |
WO (1) | WO2010096011A1 (es) |
ZA (1) | ZA201106821B (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5203360B2 (ja) * | 2006-06-23 | 2013-06-05 | アボット・ラボラトリーズ | ヒスタミンh3受容体調節剤としてのシクロプロピルアミン誘導体 |
US9108948B2 (en) * | 2006-06-23 | 2015-08-18 | Abbvie Inc. | Cyclopropyl amine derivatives |
JP4691669B2 (ja) * | 2007-08-22 | 2011-06-01 | アストラゼネカ・アクチエボラーグ | シクロプロピルアミド誘導体 |
TW201039825A (en) | 2009-02-20 | 2010-11-16 | Astrazeneca Ab | Cyclopropyl amide derivatives 983 |
US9186353B2 (en) | 2009-04-27 | 2015-11-17 | Abbvie Inc. | Treatment of osteoarthritis pain |
CN103140481A (zh) * | 2010-02-18 | 2013-06-05 | 阿斯利康(瑞典)有限公司 | 包含环丙基酰胺衍生物的固体形式 |
KR20130002316A (ko) * | 2010-02-18 | 2013-01-07 | 아스트라제네카 아베 | 시클로프로필 벤즈아미드 유도체의 신규 결정질 형태 |
WO2012037258A1 (en) | 2010-09-16 | 2012-03-22 | Abbott Laboratories | Processes for preparing 1,2-substituted cyclopropyl derivatives |
MY195948A (en) | 2016-03-22 | 2023-02-27 | Merck Sharp & Dohme | Allosteric Modulators of Nicotinic Acetylcholine Receptors |
WO2022059779A1 (ja) | 2020-09-18 | 2022-03-24 | 大日本住友製薬株式会社 | アミン誘導体 |
Family Cites Families (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE637271A (es) | 1963-04-04 | 1900-01-01 | ||
NL128365C (es) | 1963-11-05 | |||
US3449427A (en) | 1965-06-03 | 1969-06-10 | Smithkline Corp | Aminocyclopropane derivatives of 5h-dibenzo(a,d)cycloheptenes |
US3697506A (en) | 1970-08-07 | 1972-10-10 | Pfizer | Crystalline alkali metal salts of {60 -carboxybenzylpenicillin and process therefor |
US3686335A (en) | 1970-12-21 | 1972-08-22 | Smith Kline French Lab | 5-vinyl-5h-di benzo(a,d)cycloheptenes |
US4432987A (en) | 1982-04-23 | 1984-02-21 | Pfizer Inc. | Crystalline benzenesulfonate salts of sultamicillin |
US4547505A (en) | 1983-03-25 | 1985-10-15 | Degussa Aktiengesellschaft | N-Phenyl-N-'-cycloalkylalkanoylpiperazine useful as analgetics and process for its production |
CS244821B2 (en) | 1983-06-16 | 1986-08-14 | Boehringer Ingelheim Ltd | Production method of new substituted phenylalkyl(piperazinyl or homopiperazinyle)-prpylureas or thioureas |
DE3418167A1 (de) | 1984-05-16 | 1985-11-21 | Bayer Ag, 5090 Leverkusen | Verwendung von amiden zur verbesserung der kulturpflanzen-vertraeglichkeit von herbizid wirksamen heteroaryloxyacetamiden |
DE3600288A1 (de) | 1986-01-08 | 1987-07-16 | Bayer Ag | Verwendung von amiden zur verbesserung der kulturpflanzen-vertraeglichkeit von herbizid wirksamen sulfonylharnstoff-derivaten |
DE3618004A1 (de) | 1986-05-28 | 1987-12-03 | Bayer Ag | Verwendung von amiden zur verbesserung der kulturpflanzen-vertraeglichkeit von herbizid wirksamen sulfonyliso(thio)-harnstoff-derivaten |
EP0507863A4 (en) | 1989-12-28 | 1993-07-07 | Virginia Commonwealth University | Sigma receptor ligands and the use thereof |
EP0435320B1 (en) | 1989-12-29 | 1994-10-05 | Banyu Pharmaceutical Co., Ltd. | 2(2-Cyclopropylpyrrolidin-4-ylthio)-carbapenem derivatives |
EP0531271A1 (en) | 1991-08-22 | 1993-03-10 | Monsanto Company | Safening herbicidal pyrazolysulfonylureas |
DE4131139A1 (de) | 1991-09-19 | 1993-03-25 | Bayer Ag | Verfahren zur herstellung von 1-fluor-cyclopropan-1-carbonsaeure |
DE69427469T2 (de) | 1993-03-12 | 2001-10-31 | Upjohn Co | Kristallines ceftiofur (freie säure) |
JP2941950B2 (ja) | 1994-11-23 | 1999-08-30 | ニューロゲン コーポレイション | 或る種の4−アミノメチル−2−置換イミダゾール誘導体および2−アミノメチル−4−置換イミダゾール誘導体;新規な種類のドーパミン リセプタ亜型特異性リガンド |
US5604253A (en) | 1995-05-22 | 1997-02-18 | Merck Frosst Canada, Inc. | N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors |
US5859246A (en) | 1997-01-30 | 1999-01-12 | Neurogen Corporation | 1-phenyl-4-benzylpiperazines: dopamine receptor subtype specific ligands |
US6124299A (en) | 1997-02-24 | 2000-09-26 | Zymogenetics, Inc. | Calcitonin mimetics |
US6160134A (en) | 1997-12-24 | 2000-12-12 | Bristol-Myers Squibb Co. | Process for preparing chiral cyclopropane carboxylic acids and acyl guanidines |
ZA99607B (en) | 1998-01-27 | 1999-07-27 | Rhone Poulenc Rorer Pharma | Substituted oxoazaheterocyclyl factor xa inhibitors. |
US6268367B1 (en) | 1998-02-23 | 2001-07-31 | Zymogenetics, Inc. | Piperazine derivatives for treating bone deficit conditions |
EP1090919A4 (en) | 1998-06-26 | 2002-05-22 | Chugai Pharmaceutical Co Ltd | L-ALPHA-AMINOADIPIC ACID DERIVATIVE IN FINE POWDER, ORAL SOLID PREPARATIONS CONTAINING SAID DERIVATIVE AND BULK POWDER PROCESSING PROCESS |
WO2000040572A1 (en) | 1999-01-08 | 2000-07-13 | Neurogen Corporation | 1-phenyl-4-(1-[2-aryl]cyclopropyl) methylpiperazines: dopamine receptor ligands |
US6284761B1 (en) | 1999-01-08 | 2001-09-04 | Neurogen Corporation | 1-phenyl-4-(1-[2-aryl]cyclopropyl)methylpiperazines: dopamine receptor ligands |
CA2380860A1 (en) | 1999-06-16 | 2000-12-21 | Takeda Chemical Industries, Ltd. | Benzazepine derivative, production and use thereof |
AU7715300A (en) | 1999-09-27 | 2001-04-30 | Merck & Co., Inc. | Method of preventing osteoporosis |
WO2001051919A2 (en) | 2000-01-07 | 2001-07-19 | Transform Pharmaceuticals, Inc. | High-throughput formation, identification, and analysis of diverse solid-forms |
WO2002002522A1 (en) | 2000-06-29 | 2002-01-10 | Abbott Laboratories | Aryl phenycyclopropyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents |
US6521619B2 (en) | 2000-06-29 | 2003-02-18 | Icos Corporation | Aryl phenylcyclopropyl sulfide derivatives and their use as cell adhesion inhibiting anti-inflammatory and immune suppressive agents |
US6723730B2 (en) | 2000-07-20 | 2004-04-20 | Neurogen Corporation | Capsaicin receptor ligands |
JPWO2002051781A1 (ja) | 2000-12-25 | 2004-04-22 | 味の素株式会社 | 光学活性ハロヒドリン化合物の製造方法 |
PL364625A1 (en) | 2001-02-23 | 2004-12-13 | Merck & Co, Inc. | N-substituted nonaryl-heterocyclic nmda/nr2b antagonists |
JP2005502623A (ja) | 2001-07-02 | 2005-01-27 | ノボ ノルディスク アクティーゼルスカブ | 置換ピペラジンおよびジアゼパン |
WO2003014110A1 (fr) | 2001-08-08 | 2003-02-20 | Takeda Chemical Industries, Ltd. | Derive de benzazepine, son procede de preparation et d'utilisation |
CA2457642C (en) | 2001-09-26 | 2009-01-06 | Merck & Co., Inc. | Crystalline forms of ertapenem sodium |
AU2002363236A1 (en) | 2001-10-30 | 2003-05-12 | Millennium Pharmaceuticals, Inc. | Compounds, pharmaceutical compositions and methods of use therefor |
US6861432B2 (en) | 2001-11-23 | 2005-03-01 | Schering Aktiengesellschaft | Piperazine derivatives that destabilize androgen receptors |
EP1487826A4 (en) | 2002-03-22 | 2005-06-29 | Lg Life Sciences Ltd | NOVEL (2S) -N-5- (AMINO (IMINO) METHYL) -2-THIENYLMETHYL-1- (2R) -2 - ((CARBOXYMETHYL) AMINO) -3,3-DIPHENYLPROPANOYL-2-PYRROLIDINECARBOXAMIDE CRYSTALLINE FORMS. nH2O |
AU2003236686A1 (en) | 2002-06-07 | 2003-12-22 | Altana Pharma Ag | 4,5-dihydro-imidazo(4,5,1-j) quinolin-6-ones as parp inhibitors |
US20040077618A1 (en) | 2002-10-22 | 2004-04-22 | Bennani Youssef L. | Cycloalkylamides and their therapeutic applications |
US20040209858A1 (en) | 2002-10-22 | 2004-10-21 | Bennani Youssef L. | Cycloalkylamides and their therapeutic applications |
WO2004046110A1 (ja) | 2002-11-15 | 2004-06-03 | Yamanouchi Pharmaceutical Co., Ltd. | メラニン凝集ホルモン受容体拮抗剤 |
ATE384724T1 (de) | 2002-12-13 | 2008-02-15 | Smithkline Beecham Corp | Cyclopropylverbindungen als ccr5 antagonisten |
DK1615909T3 (da) | 2003-04-23 | 2008-11-17 | Glaxo Group Ltd | Piperazin-derivater og deres anvendelse til behandling af neurologiske og psykiatriske sygdomme |
PL1618092T3 (pl) | 2003-05-01 | 2011-02-28 | Bristol Myers Squibb Co | Związki amidopirazolowe z podstawnikami arylowymi jako inhibitory kinazy |
AR045595A1 (es) | 2003-09-04 | 2005-11-02 | Vertex Pharma | Composiciones utiles como inhibidores de proteinas quinasas |
CN1901971A (zh) | 2003-12-15 | 2007-01-24 | 日本烟草产业株式会社 | 环丙烷化合物及其药物应用 |
AU2004321997A1 (en) | 2004-07-06 | 2006-02-09 | Xenon Pharmaceuticals Inc. | Nicotinamide derivatives and their use as therapeutic agents |
AR050865A1 (es) | 2004-09-09 | 2006-11-29 | Sanofi Aventis | Derivados de 2- morfolino-4-pirimidona |
KR20070057931A (ko) | 2004-09-29 | 2007-06-07 | 미쯔비시 웰 파마 가부시키가이샤 | 타우 단백질 키나아제 1 저해제로서의6-(피리디닐)-4-피리미돈 유도체 |
EP1802307B1 (en) | 2004-10-15 | 2008-02-27 | Glaxo Group Limited | Pyrrolidine derivatives as histamine receptors ligands |
CN101128435A (zh) | 2004-12-27 | 2008-02-20 | 阿斯利康(瑞典)有限公司 | 作为代谢型谷氨酸受体激动剂用于治疗神经病学及精神病学病症的吡唑酮化合物 |
WO2006079916A1 (en) | 2005-01-26 | 2006-08-03 | Pharmacia & Upjohn Company Llc | Thieno [2,3-d] pyrimidine compounds as inhibitors of adp-mediated platelets aggregation |
TW200640863A (en) | 2005-02-15 | 2006-12-01 | Glaxo Group Ltd | Compounds which potentiate glutamate receptor and uses thereof in medicine |
ES2433290T3 (es) | 2005-02-17 | 2013-12-10 | Astellas Pharma Inc. | Derivados de piperazina para el tratamiento de la incontinencia urinaria y el dolor |
WO2006100591A1 (en) | 2005-03-25 | 2006-09-28 | Pharmacia & Upjohn Company Llc | 4-piperazinnylthieno [2,3-d] pyrimidine compounds as platelet aggregation inhibitors |
WO2006103545A1 (en) | 2005-03-28 | 2006-10-05 | Pharmacia & Upjohn Company Llc | 4-piperazinylthieno [2,3-d] pyrimidine compounds as platelet aggregation inhibitors |
CA2602538A1 (en) | 2005-03-28 | 2006-10-05 | Pharmacia & Upjohn Company Llc | 4-piperazinothieno [2, 3-d] pyrimidine compounds as platelet aggregation inhibitors |
WO2006103544A2 (en) | 2005-03-28 | 2006-10-05 | Pharmacia & Upjohn Company Llc | 4-piperazinylthieno [2, 3-d] pyrimidine compounds as platelet aggregation inhibitors |
EP1924568A1 (en) | 2005-07-15 | 2008-05-28 | Schering Corporation | Quinazoline derivatives useful in cancer treatment |
TW200740779A (en) | 2005-07-22 | 2007-11-01 | Mitsubishi Pharma Corp | Intermediate compound for synthesizing pharmaceutical agent and production method thereof |
EP1909797A4 (en) | 2005-08-02 | 2013-02-27 | Neurogen Corp | DIPIPERAZINYL KETONE AND RELATED ANALOG |
NZ566533A (en) | 2005-09-16 | 2010-11-26 | Janssen Pharmaceutica Nv | Cyclopropyl amines as modulators of the histamine H3 receptor |
US8158673B2 (en) | 2005-10-27 | 2012-04-17 | Pfizer Inc. | Histamine-3 receptor antagonists |
MY151028A (en) | 2005-10-31 | 2014-03-31 | Janssen Pharmaceutica Nv | Novel processes for the preparation of cyclopropyl-amide derivatives |
CN101365686A (zh) | 2005-12-21 | 2009-02-11 | 沃泰克斯药物股份有限公司 | 作为离子通道调节剂的杂环衍生物 |
US8119668B2 (en) | 2005-12-23 | 2012-02-21 | Nelson Erik B | Treatment methods employing histamine H3 receptor antagonists, including betahistine |
EP1976840A1 (en) | 2006-01-13 | 2008-10-08 | F.Hoffmann-La Roche Ag | Cyclohexyl piperazinyl methanone derivatives and their use as histamine h3 receptor modulators |
CN101384581B (zh) | 2006-02-17 | 2013-09-18 | 弗·哈夫曼-拉罗切有限公司 | 作为5ht2/d3调节剂的苯甲酰基-哌啶衍生物 |
US20100006010A1 (en) | 2006-03-01 | 2010-01-14 | Ihor Hinczak | Matrix for masonry elements and method of manufacture thereof |
JP2009132621A (ja) | 2006-03-13 | 2009-06-18 | Ajinomoto Co Inc | シクロプロピルアミド化合物の製造方法 |
EP2004619A1 (en) | 2006-03-23 | 2008-12-24 | Amgen Inc. | 1-phenylsulfonyl-diaza heterocyclic amide compounds and their uses as modulators of hydroxsteroid dehydrogenases |
JP5301270B2 (ja) | 2006-05-26 | 2013-09-25 | 株式会社カネカ | 光学活性3−アミノ−2−ヒドロキシプロピオン酸シクロプロピルアミド誘導体およびその塩の製造方法 |
US9108948B2 (en) | 2006-06-23 | 2015-08-18 | Abbvie Inc. | Cyclopropyl amine derivatives |
JP5203360B2 (ja) * | 2006-06-23 | 2013-06-05 | アボット・ラボラトリーズ | ヒスタミンh3受容体調節剤としてのシクロプロピルアミン誘導体 |
AU2007271187A1 (en) | 2006-07-03 | 2008-01-10 | Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg | Fused bicyclic compounds interacting with the histamine H4 receptor |
US20090247499A1 (en) | 2006-08-21 | 2009-10-01 | Fletcher Joan M | Sulfonylated piperazines as cannabinoid-1 receptor modulators |
TW200828371A (en) | 2006-09-21 | 2008-07-01 | Matsushita Electric Ind Co Ltd | Chip-type filter |
DE102006056526A1 (de) | 2006-11-30 | 2008-06-05 | Archimica Gmbh | Verfahren zur stereoselektiven Synthese von chiralen Epoxiden durch ADH-Reduktion von alpha-Abgangsgruppen-substituierten Ketonen und Cyclisierung |
US7737149B2 (en) | 2006-12-21 | 2010-06-15 | Astrazeneca Ab | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof |
WO2008147864A2 (en) * | 2007-05-22 | 2008-12-04 | Xenon Pharmaceuticals Inc. | Methods of using piperazine compounds in treating sodium channel-mediated diseases or conditions |
WO2008150364A1 (en) | 2007-05-23 | 2008-12-11 | Merck & Co., Inc. | Cyclopropyl pyrrolidine orexin receptor antagonists |
ES2350511T3 (es) * | 2007-06-11 | 2011-01-24 | F. Hoffmann-La Roche Ag | Derivados ciclohexilo. |
JP4691669B2 (ja) * | 2007-08-22 | 2011-06-01 | アストラゼネカ・アクチエボラーグ | シクロプロピルアミド誘導体 |
WO2009043784A1 (en) | 2007-10-04 | 2009-04-09 | F. Hoffmann-La Roche Ag | Cyclopropyl aryl amide derivatives and uses thereof |
PE20091313A1 (es) | 2008-01-15 | 2009-09-03 | Lilly Co Eli | (r)-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida cristalina |
DE102008049371A1 (de) | 2008-03-06 | 2009-09-10 | Mühlbauer Ag | Einrichtung mit einem RFID-Transponder in einem elektrisch leitfähigen Gegenstand und Herstellungsverfahren hierfür |
JP5780954B2 (ja) | 2008-05-08 | 2015-09-16 | エヴォテック・アクチエンゲゼルシャフト | ヒスタミンh3受容体アンタゴニストとしてのアゼチジン類及びシクロブタン類 |
CN102137836B (zh) | 2008-07-28 | 2015-08-26 | 赛丹思科大学 | 用于治疗代谢疾病的化合物 |
CN101462980B (zh) | 2009-01-05 | 2013-01-09 | 扬州天辰精细化工有限公司 | 2,6—二氟苯甲酰胺的工业化生产方法 |
TW201039825A (en) | 2009-02-20 | 2010-11-16 | Astrazeneca Ab | Cyclopropyl amide derivatives 983 |
KR20130002316A (ko) | 2010-02-18 | 2013-01-07 | 아스트라제네카 아베 | 시클로프로필 벤즈아미드 유도체의 신규 결정질 형태 |
CN103140481A (zh) * | 2010-02-18 | 2013-06-05 | 阿斯利康(瑞典)有限公司 | 包含环丙基酰胺衍生物的固体形式 |
-
2010
- 2010-02-12 TW TW099104778A patent/TW201039825A/zh unknown
- 2010-02-17 SA SA110310136A patent/SA110310136B1/ar unknown
- 2010-02-19 AR ARP100100499A patent/AR075531A1/es unknown
- 2010-02-19 EP EP10744028.1A patent/EP2398780B1/en active Active
- 2010-02-19 WO PCT/SE2010/050191 patent/WO2010096011A1/en active Application Filing
- 2010-02-19 UY UY0001032460A patent/UY32460A/es not_active Application Discontinuation
- 2010-02-19 RS RS20130280A patent/RS52851B/en unknown
- 2010-02-19 PE PE2015001189A patent/PE20151281A1/es not_active Application Discontinuation
- 2010-02-19 PE PE2011001527A patent/PE20120063A1/es not_active Application Discontinuation
- 2010-02-19 DK DK10744028.1T patent/DK2398780T3/da active
- 2010-02-19 CA CA2752796A patent/CA2752796A1/en not_active Abandoned
- 2010-02-19 CN CN201080017452.0A patent/CN102405213B/zh not_active Expired - Fee Related
- 2010-02-19 CN CN201410557796.0A patent/CN104398516A/zh active Pending
- 2010-02-19 BR BRPI1007817A patent/BRPI1007817A2/pt not_active IP Right Cessation
- 2010-02-19 KR KR1020117019311A patent/KR20110126628A/ko not_active Application Discontinuation
- 2010-02-19 AU AU2010216454A patent/AU2010216454B2/en not_active Ceased
- 2010-02-19 SI SI201030257T patent/SI2398780T1/sl unknown
- 2010-02-19 ES ES10744028T patent/ES2416464T3/es active Active
- 2010-02-19 UA UAA201109215A patent/UA108841C2/ru unknown
- 2010-02-19 SG SG2011053477A patent/SG173449A1/en unknown
- 2010-02-19 MX MX2011008280A patent/MX2011008280A/es active IP Right Grant
- 2010-02-19 US US12/708,550 patent/US8993577B2/en not_active Expired - Fee Related
- 2010-02-19 EA EA201190140A patent/EA020093B1/ru not_active IP Right Cessation
- 2010-02-19 PL PL10744028T patent/PL2398780T3/pl unknown
- 2010-02-19 JP JP2011551039A patent/JP5666480B2/ja not_active Expired - Fee Related
- 2010-02-19 ME MEP-2013-74A patent/ME01619B/me unknown
- 2010-02-19 NZ NZ595248A patent/NZ595248A/en not_active IP Right Cessation
- 2010-02-19 EA EA201490268A patent/EA201490268A1/ru unknown
- 2010-02-19 PT PT107440281T patent/PT2398780E/pt unknown
-
2011
- 2011-07-25 IL IL214277A patent/IL214277A/en not_active IP Right Cessation
- 2011-07-29 CO CO11095921A patent/CO6400219A2/es active IP Right Grant
- 2011-08-19 NI NI201100160A patent/NI201100160A/es unknown
- 2011-08-19 SV SV2011004008A patent/SV2011004008A/es unknown
- 2011-08-19 DO DO2011000270A patent/DOP2011000270A/es unknown
- 2011-08-19 EC EC2011011280A patent/ECSP11011280A/es unknown
- 2011-08-19 HN HN2011002261A patent/HN2011002261A/es unknown
- 2011-08-19 CR CR20110447A patent/CR20110447A/es unknown
- 2011-08-19 CU CU20110161A patent/CU20110161A7/es unknown
- 2011-09-19 ZA ZA2011/06821A patent/ZA201106821B/en unknown
-
2012
- 2012-06-07 HK HK12105548.2A patent/HK1164863A1/xx not_active IP Right Cessation
-
2013
- 2013-06-21 HR HRP20130579AT patent/HRP20130579T1/hr unknown
- 2013-07-04 SM SM201300077T patent/SMT201300077B/xx unknown
-
2014
- 2014-02-06 CU CU2014000013A patent/CU20140013A7/es unknown
- 2014-12-09 JP JP2014248499A patent/JP2015071634A/ja active Pending
-
2015
- 2015-02-24 US US14/630,514 patent/US20150164888A1/en not_active Abandoned
- 2015-02-24 US US14/630,530 patent/US20150164889A1/en not_active Abandoned
- 2015-09-11 HK HK15108903.2A patent/HK1208348A1/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CU20140013A7 (es) | Derivados de ciclopropilamida dirigidos contra el receptor de histamina h3 | |
NI201000031A (es) | Derivados de ciclopropilamida. | |
CR11684A (es) | Dihidropirazolonas sustituidas de hif-propil-4- como inhibidores hidroxilasa | |
ECSP11011526A (es) | Aril-piridinas como inhibidoras de sintasa de aldosterona | |
CO6430459A2 (es) | Derivados de prolina como inhibidores de catepsina | |
MX2011011733A (es) | Inhiibidores de dihidroorotato deshidrogenasa como compuestos virostaticos. | |
UY33075A (es) | Derivados de ciclohexano y usos de los mismos | |
GT201300258A (es) | Derivados de pirazoloespirocetona para uso como inhibidores de acetil-coa carboxilasa | |
CO6410298A2 (es) | Pirimidinas fusionadas | |
CO6362012A2 (es) | Clohidarto de nalmefeno dihidratado | |
CR20130530A (es) | Derivados glucósidos y sus usos para el tratamiento de la diabetes | |
PA8846201A1 (es) | Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), producción y uso de los mismos como productos medicinales | |
CO6382130A2 (es) | Nuevos compuestos de imidazolidina como moduladores del receptor de androdenos | |
MX2011011229A (es) | Metodo para reducir la presion intraocular en los seres humanos. | |
ECSP099754A (es) | Derivados de la espirociclopropil piperidina | |
UY31903A (es) | 7-sulfanilmetil-,7-silfinilmetil-y7-sulfonilmetilindoles sustituidos y el uso de los mismos | |
UY32258A (es) | Derivados de la espirociclobutilpiperidina | |
ATE481395T1 (de) | Cyclohexylderivate | |
UY30974A1 (es) | Metodo para tratar el dolor mediado por los receptores de cb2 (ii) | |
UY31303A1 (es) | Derivados de ciclopropil amida 978 | |
GT200800195A (es) | Procedimiento para la preparación de derivados de ciclopropilamida | |
CY1114176T1 (el) | Παραγωγα κυκλοπροπυλαμιδιου που στοχευουν τον υποδοχεα η3 της ισταμινης | |
CY1116993T1 (el) | Μεθοδος μειωσης της ενδοφθαλμιας πιεσης σε ανθρωπους | |
CL2010000497A1 (es) | Uso de compuestos derivados de indol para el tratamiento del dolor visceral; compuestos específicos derivados de indol; procedimiento de preparación de un compuesto; composición farmacéutica y uso para el tratamiento de una condición causada por la acción de nos. | |
ECSP10010028A (es) | Tratamiento de síntomas vasomotores |